Christoph Huber

Christoph Huber is a prominent figure in the field of cancer immunotherapy with extensive experience in various leadership roles. Since 2008, Christoph Huber has served as Cofounder and Deputy Chairman of the Supervisory Board at BioNTech SE, a company focused on innovative RNA- or VLP-based tumor vaccines and related technologies. Additionally, Christoph Huber has been a Member of the Supervisory Board at TRON-Mainz since 2009 and has played a crucial role as Chairman of the Board of Directors for the Association for Cancer Immunotherapy CIMT since its inception in 2002. As Cofounder and Deputy Chairman of Ganymed Pharmaceuticals since 2001, Christoph Huber has also contributed significantly to the advancement of cancer treatment. Previously, from 1990 to 2009, Christoph Huber was Chairman of the Department of Hematology & Oncology at Universitätsmedizin Mainz. Christoph Huber earned a medical degree (MD) from Medizinische Universität Innsbruck in 1968.